Breast Cancer
-
Forward Look
Early Chemotherapy Dose Reductions May Affect Breast Cancer OutcomesNew study explores impact of lowering dose due to side effects.
by Jane Langille
-
Medicare Coverage for Next-Generation Sequencing TestsMultigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.
by Ashley P. Taylor
-
On Cancer and IdentityThe first time Liza Bernstein was diagnosed with cancer, she wouldn't allow it to be part of her identity. After her third cancer diagnosis, she became an advocate for other patients.
by Liza Bernstein
-
Forward Look
A New Use for Patient DataGregory Daniel on real-world evidence for cancer drug approvals.
by Sue Rochman
-
Telling Your Children About Inheritable Cancer RiskLetting children know they might have a mutation that increases their risk for cancer can be a challenge for patients. Experts stress there is no right or wrong way to share the information.
by Marci A. Landsmann
-
The Right DoseResearchers want to find out when cancer patients can benefit from receiving lower doses of drugs or radiation, shortening treatment or skipping certain treatments altogether.
by Kate Yandell
-
Cancer Patient Advocates Find Strength in NumbersPatient advocates have become a vital part of the San Antonio Breast Cancer Symposium. Opportunities for advocates continue to multiply.
by Marci A. Landsmann
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
